Strategy for prevention of hip fractures in patients with Parkinson’s disease

Table 1 Identified randomized controlled trials of efficacy of interventions against hip fractures in patients with Parkinson’s disease

		Number of study subjects
Interventions	Groups	Randomized	Dropped out	Completed	Average age (yr)	Average duration of illness (yr)	Vitamin D supplementation	Study period (yr)
Sunlight exposure[12]	Sunlight exposure	162	6	156	75.4	4.2	None	2
(men/women)	Usual lifestyle	162	8	154	75.2	4.1
menatetrenone[13]	Menatetrenone	60	4	56	72.3	4.8	None	1
(women)	Non-treatment	60	6	54	71.6	4.9
Daily alendronate[14]	Alendronate	144	13	131	72.2	5.1	Ergocalciferol (1000 IU/d)	2
(women)	Placebo	144	15	129	72.2	5.1
Daily risedronate[15]	Risedronate	121	10	111	71.3	4.9	Ergocalciferol (1000 IU/d)	2
(men)	Placebo	121	9	112	71.3	4.9
Weekly risedronate[16]	Risedronate	136	10	126	74.4	4.8	Ergocalciferol (1000 IU/d)	2
(women)	Placebo	136	12	124	74.4	4.9